DIOSMIN ( DrugBank: Diosmin )


1 disease
IDDisease name (Link within this page)Number of trials
265Lipodystrophy1

265. Lipodystrophy


Clinical trials : 116 Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-004539-57-PL
(EUCTR)
30/01/201416/12/2013A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite)A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite) lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite)
MedDRA version: 17.0;Level: LLT;Classification code 10065339;Term: Cellulite;System Organ Class: 100000004858
MedDRA version: 17.0;Classification code 10043193;Term: Telangiectasis;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Diosminex, 500 mg, tabletki powlekane
INN or Proposed INN: diosmin
Other descriptive name: DIOSMIN
ALIO MEDICA Sp. z o.o.NULLNot RecruitingFemale: yes
Male: no
Phase 3Poland